Skip to main content
QNTM
NASDAQ Life Sciences

Quantum BioPharma's MS Imaging Study with MGH Hits Midpoint, Showing Promising Early Data

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.705
Mkt Cap
$39.697M
52W Low
$2.07
52W High
$38.25
52W Position info
224% above low
Off High info
82% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

QNTM has more than doubled off its 52-week low of $2.07.

Summary

Quantum BioPharma announced a significant midpoint milestone in its collaborative imaging study with Massachusetts General Hospital, reporting encouraging preliminary data. This study is validating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to assess demyelination in multiple sclerosis (MS) patients, which could significantly enhance the evaluation of therapies like Quantum's investigational candidate, Lucid-MS. The preliminary analyses indicate robust signals in acute MS lesions. This positive development follows the company's recent IND filing for Lucid-MS in March 2026 and its strengthened liquidity. The successful validation of this imaging approach could accelerate the development and de-risk future clinical trials for Lucid-MS, providing a more precise measure of treatment impact on myelin preservation and regeneration. Investors should watch for further updates on both the imaging study's full results and the progression of Lucid-MS into Phase 2 clinical trials.

At the time of this announcement, QNTM was trading at $6.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $2.07 to $38.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

QNTM - Latest Insights

QNTM
Nov 12, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $1.60 info
Change: -$0.180 (-10%) info
Market Cap: $13.021M info
QNTM
Nov 12, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.60 info
Change: -$0.400 (-20%) info
Market Cap: $13.021M info
QNTM
Oct 08, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $1.60 info
Change: -$1.49 (-48%) info
Market Cap: $13.021M info
QNTM
Oct 06, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.27
Real-time Price: $1.60 info
Change: -$1.67 (-51%) info
Market Cap: $13.021M info
QNTM
Sep 01, 2026, 8:28 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $1.60 info
Change: -$1.42 (-47%) info
Market Cap: $13.021M info